TScan Therapeutics falls after pausing cancer trial
TCRX•Shares fall after trial pause and funding concern
Shares of drug developer TScan Therapeutics (TCRX.O) fell 9.9% to 60 cents premarket after the company said it is pausing enrollment in a late-stage trial of its experimental blood-cancer therapy TSC-101 because it lacks the funds to complete the study.
Restructuring, partnership search and solid-tumor focus
The company said it will seek a partner for its blood-cancer and autoimmune-disease programs as it shifts focus to experimental cell therapies for solid tumors.
It plans to begin early-stage human trials of two solid-tumor treatments in the fourth quarter of 2027.
TScan also said it will cut about 75% of its workforce, close internal manufacturing operations and reduce research activities.
The restructuring is expected to save $55 million through 2027 and extend its cash runway into the fourth quarter of 2027.
As of the last close, TCRX was down 33.4% year to date.
